Clinical Trials Logo

Clinical Trial Summary

Based on animal studies, it was found that administration of endothelial receptor antagonists before and after renal blood vessels clamp and release results in a significantly reduced renal function injury.

On the basis of these results, we chose to divide the study population into 2 groups: control group that would be treated the standard accepted preventive treatment: intravenous injection of Mannitol, cooling of the kidney surface, compared to the treatment group that in addition would receive pre- and post-operative treatment of endothelial receptor antagonists (Ambrisentan (Volibris (10mg).

To be noticed that the drug is recognized and is given as a primary indication for patients with pulmonary hypertension.

The differences between the renal function and biomarkers for pre- and post-operative renal ischemic injury would be examined in order to disclose if the kidney injury of the treated group was indeed smaller.

This information will enable us to protect the operated kidneys from the ischemic damage, especially in those patients with poor basic renal function.


Clinical Trial Description

This is a study aimed at examining the protective effect of endothelin antagonism on the ischemic damage the kidney undergoes during partial nephrectomy for kidney lesion removal.

In such procedure, it is common to clamp the kidney blood vessels in order to eliminate blood flow in the surgical field that will enable clear visibility to differentiate the tumor tissue from the normally kidney parenchyma.

Later, after removing the tumor lesion and suturing the tumor bed, the blockage is released and the renal blood flow returns.

The blockage itself and its release causes damage to the kidney tissue that is usually reduced by the kidney's cooling (through ice crystals)and as well as intravenous injection of mannitol.

In this study, patients were divided into 2 groups randomly, assigned the receipt in the order of recruitment.

The first group will receive the standard treatment and the other will be given before and after surgery endothelin antagonists in addition to the standard treatment. The drug will be given once a day for 5 days, starting 48 hours before surgery. Treatment efficacy assessment will be based on comparison of renal function (serum creatinine level and glomerular filtration) as well as biomarkers of acute renal damage (NGAL, KIM-1, and others) that will be taken from patients before and at different time points after surgery: urine samples to be taken at the following time points: - 3 , 8,24,48,72 hours after surgery. Blood samples will be taken at the following time points: - 8, 24, 48, 72 hours after surgery. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04450095
Study type Interventional
Source Bnai Zion Medical Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date October 11, 2018
Completion date October 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT00982527 - Fenoldopam in Pediatric Cardiac Surgery Phase 3
Completed NCT00908843 - Prevention of Contrast Induced Nephropathy (NIC) by Intravenous Versus Oral Rehydration N/A
Completed NCT00654992 - Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery Phase 2/Phase 3
Completed NCT05407272 - Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care N/A
Not yet recruiting NCT05399420 - Study of Kidney Circulating Cell-free DNA in Patients With Acute Kidney Failure
Recruiting NCT04334707 - Kidney Precision Medicine Project
Completed NCT04072432 - A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3-4 Chronic Kidney Disease Phase 1
Recruiting NCT00230412 - Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study) N/A
Completed NCT00148044 - Uremic Toxins of Patients With Acute Kidney Failure N/A
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Completed NCT03353389 - Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang
Completed NCT03727581 - Ultrasound for Guidewire Detection
Completed NCT00912184 - Study Comparing High Cut-off Haemofiltration With Standard Haemofiltration in Acute Renal Failure Phase 1/Phase 2
Recruiting NCT00522756 - Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy Phase 3
Completed NCT00484354 - Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery Phase 2
Terminated NCT00316576 - Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA) N/A
Completed NCT00122018 - An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery Phase 2
Unknown status NCT01359722 - N-acetylcysteine to Prevent Renal Failure N/A
Completed NCT00286273 - Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration Phase 4
Completed NCT03476460 - Sodium Chloride and Contrast Nephropathy Phase 2